The most frequent clinical manifestation of anti-breast-cancer drug-related cardiotoxicity (ADRC) is symptomatic or asymptomatic LV dysfunction that can progress to HF.
Data available today on presentation and management of patients with ADRC come mainly from clinical trials or registries that have not been representative of the “real world”. Clinical trials often have stringent exclusion criteria, and thus do not adequately represent populations with the whole spectrum of ADRC, particularly in terms of age, co-morbidity, and concomitant therapies, and therefore do not reflect daily practice.Cardiac imaging represents a vital component in the detection and follow-up of ADRC. However, information about imaging practice in Europe is lacking. Also, how imaging and biomarkers are integrated in clinical routine in these patients remains to be determined.
Hence, a comprehensive systematic clinical assessment of breast cancer patients with ADRC in a large European registry compiling all relevant information would help to better understand how serious this disease is and how ADRC is managed and affects the outcome and quality of life of these patients in the "real" world.
Such a registry could also be the basis of the development of a specific ADRC guideline.
The ESC-COT (Cardiac-Oncology Toxicity) EACVI/HFA Pilot registry is a prospective, multicentre, observational study of patients presenting to imaging labs and followed by cardiology or oncology Centres in European countries.
Site selection in each participating country will target a sample of hospitals of different levels of complexity from which patients are to be recruited, focusing on capturing a broad spectrum of cardiology/Oncology and HF/Imaging specialty units, regularly following patients with ADRC, in order to build up a network of centres representative of the reality in Europe.
Consecutive breast cancer patients seen in an imaging lab (echo or nuclear cardiology usually) for routine surveillance of LV function or evaluation of HF symptoms or suspected ADRC and with confirmed LV dysfunction are to be enrolled in the registry. Often, this will concern patients undergoing chemotherapy with associated targeted therapy (e.g. trastuzumab), or not, at increased risk of ADRC. Outpatient visits will be performed according to the usual practice of the participating centres.
Duration of the enrolment period will starts at 12 months. Data on morbidity and mortality will be collected at 3, 6 and 12 months after the entry visit.
The registry currently includes 19 ESC member countries and 3 affiliate countries.
The main purpose of this study is to examine clinical, imaging and treatment practices for ADRC in Europe. The mains are as follows:
This registry comprises countries homogenously distributed across Europe (North, South, East, Central/West) and beyond, and was started in 2015.
The Executive Committee is chaired by Prof. Patrizio Lancellotti (EACVI) and co-chaired by Prof. Stephan Anker (HFA).
Patrizio Lancellotti (Chair), EACVIStephan Anker, (Co-Chair), HFAErwan Donal, EACVIMaurizio Galderisi, EACVIThor Edvardsen, EACVIBogdan Popescu, EACVIGilbert Habib, EACVIDimitrios Farmakis,HFAGerasimos Filippatos, HFAGuy Jerusalem, Oncologist Chiara Lestuzzi Aldo Pietro Maggioni, EORP Scientific Coordinator, ex officio (non-voting member)
The Steering Committee is composed by the chairmen of the study and by the National Coordinator of each participating country selected by the EACVI/HFA in collaboration with the National Imaging Communities.
Guy Jerusalem, BEErwan Donal, FRGilbert Habib, FRAndreas Hagendorff, DEGeorge Athanassopoulos, GRMaurizio Galderisi, ITThor Edvardsen, NOEdyta Plonska-Gosciniak, PLNuno Miguel Cardim, PTLigia Mendes, PTSimon Matskeplishvili, RUPepe Zamorano, SPMadalina Garbi, UK
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved